Sens. Klobuchar, Collins push drug-shortage bill

Share this article:
Sen. Susan Collins (R-ME)
Sen. Susan Collins (R-ME)

U.S. senators Amy Klobuchar (D-MN) and Susan Collins (R-ME) are urging their fellow lawmakers to quickly pass a bipartisan bill aimed at addressing the growing drug shortage problem in the U.S.

“The shortages of these vital drugs are causing serious problems around the country,” said Collins in a statement. “Our legislation aims to give the FDA the tools and information they need to prevent drug shortages.”

The Preserving Access to Life-Saving Medications Act, which  Klobuchar introduced  last year, would require drug companies to give  FDA six months notice of any discontinuance, interruption, or other adjustment of a drug's manufacturing process that would likely result in a shortage. Notification would be required for adjustments related to raw materials supply, production capabilities and other reasons deemed appropriate by the HHS secretary.

A stakeholders group has called for exploring incentives such as tax credits for producing critical drug products or upgrading manufacturing plants. They also recommend an expedited approval pathway.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?